ARCHIVES

NCI Advisors Criticize a Biomarker Study Touted as High Priority for NCI and FDA.

This article is from The Cancer Letter archive.

Vol. 33 No. 27 | July 13, 2007

Download PDF Visit The Full Archive

Related Articles

News Analysis by Keith Baggerly: Duke Trials Went On Despite FDA Statements

January 27, 2012

NCCS Networker Volume 4 Issue 2, Spring 1990

April 13, 1990

NCI To Fund 23 CHOPs, More Singles Than Multiples; ACCC Expresses Concern

August 8, 1980

Improvements Still Needed To Reduce Chemo Errors

November 25, 2005

Women 80 And Older Benefit From Mammography

May 30, 2008

ODAC Votes to Nix Amgen’s Drug Xgeva For Proposed Prostate Cancer Indication

February 17, 2012